Sydnexis has fully enrolled the STAR Study, its single pivotal Phase 3 study to treat the progression of myopia in children. The STAR Study is a multi-center, randomized, double masked, placebo-controlled trial evaluating two dosage strengths of SYD-101 in more than 850 children between the ages of 3-14. To learn more about the STAR Study, please visit the ClinicalTrials.gov website.